<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080739</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300003574</org_study_id>
    <nct_id>NCT04080739</nct_id>
  </id_info>
  <brief_title>Regional Block for Postoperative Free Flap Care</brief_title>
  <official_title>Regional Block for Postoperative Free Flap Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to evaluate the safety and efficacy of regional anesthesia&#xD;
      for head and neck patients undergoing microvascular free flap reconstruction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The increasing rate of opioid related overdose mortality is well documented in the literature&#xD;
      and approached 15 per 100,000 in 2017. Because of a growing epidemic in the US, the medical&#xD;
      community is under scrutiny to curtail opioid prescription. However, this is weighed against&#xD;
      surgical outcomes; importantly, postoperative pain has adverse effects on function, recovery&#xD;
      and quality of life.&#xD;
&#xD;
      Regional anesthesia provides a non opioid based, pain control strategy. First, regional&#xD;
      anesthesia decreases systemic adverse events including respiratory failure in abdominal&#xD;
      surgery, decreases length of stay and improves rehabilitation in common orthopedic procedures&#xD;
      such as total knee arthroplasty and shoulder arthroplasty. Second, the physiologic benefits&#xD;
      of regional anesthesia are compelling including augmented micro and macrocirculation,&#xD;
      maintenance of body temperature and decreased systemic stress response through chemical&#xD;
      sympathectomy. Finally, regional anesthesia has been established as safe in the microvascular&#xD;
      and anesthesia literature for pediatric, and adult patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant pain control</measure>
    <time_frame>21 days</time_frame>
    <description>Self-report of pain score on a scale of 0 to 10, with 0 being &quot;no pain&quot; and 10 being &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid medication use</measure>
    <time_frame>21 days</time_frame>
    <description>Amount of opioid medication used post-operatively, based on pill count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>US-guided ipsilateral sciatic nerve block for fibula free flap patients utilizing ropivacaine 0.2% at 2-8 cc/hr for fibula free flap patients; US-guided infraclavicular brachial plexus nerve block for forearm free lap patients utilizing ropivacaine 0.2% at 2-8cc/hr for forearm free flap patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No regional anesthetic of any kind during the surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivicaine 0.2%</intervention_name>
    <description>2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Able to consent for themselves&#xD;
&#xD;
          -  Undergoing a head and neck surgery at UAB with reconstruction using either a forearm&#xD;
             free flap or a fibula free flap&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Unable to consent for themselves&#xD;
&#xD;
          -  Non-English speakers&#xD;
&#xD;
          -  Non-resectable tumor&#xD;
&#xD;
          -  Have a known opioid tolerance, or are on a home opioid regimen for a chronic&#xD;
             condition. (Short-term opioid use for diagnostic procedures (i.e. biopsy) or new&#xD;
             cancer diagnosis will be allowed).&#xD;
&#xD;
          -  Patients with known hepatic failure, renal failure, or sulfa allergy, as determined by&#xD;
             standard of care labs drawn within 30 days of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Morlandt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Morlandt, MD</last_name>
    <phone>(205) 996-2799</phone>
    <email>amorlandt@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Morlandt, MD</last_name>
      <phone>205-996-2799</phone>
      <email>amorlandt@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Anthony Morlandt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

